Login / Signup

Nanoformulated meloxicam and rifampin: inhibiting quorum sensing and biofilm formation in Pseudomonas aeruginosa .

Malihe KhorramdelFatemeh Peyravii GhadikolaiiSeyed Isaac HashemyDr Hossein JavidMasoud Homayouni Tabrizi
Published in: Nanomedicine (London, England) (2024)
Background: We aimed to investigate the simultaneous effects of meloxicam and rifampin nanoformulations with solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) substrates on inhibiting the quorum-sensing system of Pseudomonas aeruginosa and preventing biofilm formation by this bacterium. Methods: Antimicrobial activity of rifampin and meloxicam encapsulated with SLNs and NLCs against P. aeruginosa PAO1 was assessed by disk diffusion, minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). Results: The SLN formulation was associated with lower doses for the MIC and minimum bactericidal concentration in comparison to NLC. Moreover, our results demonstrated that both nanoformulations were able to produce 100% inhibition of the biofilm formation of P. aeruginosa PAO1. Conclusion: All these findings suggest that meloxicam and rifampin encapsulated with SLNs could be the most effective formulation against P. aeruginosa .
Keyphrases
  • biofilm formation
  • pseudomonas aeruginosa
  • cystic fibrosis
  • staphylococcus aureus
  • candida albicans
  • acinetobacter baumannii
  • escherichia coli
  • signaling pathway
  • drug delivery
  • fatty acid
  • multidrug resistant